key: cord-0983157-8yu81010
authors: Benotmane, Ilies; Gautier Vargas, Gabriela; Wendling, Marie‐Josée; Perrin, Peggy; Velay, Aurélie; Bassand, Xavier; Bedo, Dimitri; Baldacini, Clement; Sagnard, Mylene; Bozman, Dogan; Della Chiesa, Margaux; Solis, Morgane; Gallais, Floriane; Cognard, Noëlle; Olagne, Jerome; Delagreverie, Héloïse; Gontard, Louise; Panaget, Baptiste; Marx, David; Heibel, Francoise; Braun, Laura; Moulin, Bruno; Caillard, Sophie; Fafi‐Kremer, Samira
title: In‐depth virological assessment of kidney transplant recipients with COVID‐19
date: 2020-08-10
journal: Am J Transplant
DOI: 10.1111/ajt.16251
sha: 23376e04e907ba823a26baca3214ad936dfdf897
doc_id: 983157
cord_uid: 8yu81010

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has spread widely, causing coronavirus disease 2019 (COVID‐19) and significant mortality. However, data on viral loads and antibody kinetics in immunocompromised populations are lacking. We aimed to determine nasopharyngeal and plasma viral loads via RT‐PCR and SARS‐CoV‐2 serology via ELISA and study their association with severe forms of COVID‐19 and death in kidney transplant recipients. In this study we examined hospitalized kidney transplant recipients with non‐severe (n = 21) and severe (n =19) COVID‐19. SARS‐CoV‐2 nasopharyngeal and plasma viral load and serological response were evaluated based on outcomes and disease severity. Ten recipients (25%) displayed persistent viral shedding 30 days after symptom onset. The SARS‐CoV‐2 viral load of the upper respiratory tract was not associated with severe COVID‐19, whereas the plasma viral load was associated with COVID‐19 severity (p=0.010) and mortality (p=0.010). All patients harbored antibodies the second week after symptom onset that persisted for two months. We conclude that plasma viral load is associated with COVID‐19 morbidity and mortality, whereas nasopharyngeal viral load is not. SARS‐CoV‐2 shedding is prolonged in kidney transplant recipients and the humoral response to SARS‐CoV‐2 does not show significant impairment in this series of transplant recipients.

In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China, and it has since spread widely across the world. 1 The resulting coronavirus disease 2019 has led to a high death toll. Scientific knowledge on SARS-CoV-2 has evolved rapidly since the outbreak, but little is known about responses to the virus in immunocompromised populations. Infection with respiratory viruses has been shown to be particularly concerning in transplant recipients due to prolonged viral shedding and a higher risk of complications. 2, 3 However, there have been no reports indicating whether SARS-CoV-2 infection presents the same risks for transplant recipients as other respiratory viruses. Determining viral loads and antibody kinetics in immunocompromised individuals is necessary to protect this highly immunocompromised population. Because prolonged viral shedding and/or a lack of protective immunity could lead to significant viral spread in patients' environments, protective measures may need to be increased.

We thus conducted a retrospective cohort study in kidney transplant recipients (KTR) in Alsace, Grand-Est France, to determine the dynamics of nasopharyngeal and plasma viral loads and SARS-CoV-2 serology and to study their association with mortality and severe forms of COVID-19.

A total of 40 adult KTR hospitalized with COVID-19 were consecutively recruited at our transplant center between March 4 and April 7, 2020. COVID-19 was diagnosed in these patients based on their clinical symptoms and positive reverse transcription-polymerase chain reaction (RT-PCR) results obtained using nasopharyngeal swabs and/or typical lung lesions observed through chest computed tomography (CT). Patient characteristics were retrieved from digital medical records from the day of admission through the date of last follow-up (May 13, 2020).

Data for the following parameters were collected: demographic variables, symptoms and time of presentation, immunosuppressive therapy and management, laboratory parameters, chest CT findings, administered drugs, death, and intensive care unit (ICU) admissions. In accordance with the published literature, 4-7 patients were considered to have severe COVID-19 in presence of at least one of the following criteria: oxygen requirement >6 L/min; need for ICU admission; and

This article is protected by copyright. All rights reserved death. The study protocol was reviewed and approved by the local Institutional Review Board (approval number: DC-2013-1990).

In keeping with the COVID-HUS study protocol (ClinicalTrials.gov identifier: NCT04405726), quantitative RT-PCR tests for SARS-CoV-2 nucleic acid were performed using nasopharyngeal swabs and plasma samples obtained at admission and on a weekly basis during follow-up until discharge for all but one patient -whose nasopharyngeal swab was collected at another laboratory at the time of diagnosis. Afterwards, nasopharyngeal swab testing was performed at 30, 45, and 60 days after the date of symptom onset. Primer and probe sequences targeted two regions on the RNA-dependent RNA polymerase (RdRp) gene specific to SARS-CoV-2. SARS-CoV-2 RNA was quantified using serial 10-fold dilutions of SARS-CoV-2 RNA transcript at a concentration of 10 9 copies/µL. The assay's sensitivity was approximately 10 RNA copies per reaction. A SARS-CoV-2 RT-PCR result was considered positive when at least one of the targets was amplified (Supplementary Material). 8 Viral clearance was defined as at least one negative RT-PCR test in nasopharyngeal swabs.

Immunoglobulin (Ig) M and IgG antibody responses to SARS-CoV-2 recombinant nucleocapsid and spike antigens were tested using a commercially available enzyme-linked immunosorbent assay (ELISA; DIA.PRO Diagnostic BioProbes Srl, Sesto San Giovanni, Italy) according to the manufacturer's instructions. Antibody levels are presented as measured absorbance values divided by the cutoff (S/CO). The cutoff value was defined as the mean absorbance values of the three negative controls plus 0.250. IgM and IgG specificity and sensitivity reached an overall value of ≥ 98%. Seronegative patients were negative for IgM and IgG.

Continuous data are presented as medians and interquartile ranges (IQR) and were analyzed using the non-parametric Mann-Whitney U test. Categorical variables are expressed as counts and percentages and were compared using the Fisher's exact test. The associations between maximum nasopharyngeal and plasma SARS-CoV-2 viral loads and clinical, demographic, and laboratory variables were determined using Spearman's correlation coefficient (ρ) values. Receiver operating

This article is protected by copyright. All rights reserved characteristic (ROC) curves were generated to investigate the viral loads in the upper respiratory tract and plasma with respect to disease severity and mortality. Survival plots of severe COVID-19-free survival and COVID-19-specific survival were graphically represented with Kaplan-Meier curves according to RNAaemia (i.e., positive plasma viral load), using the log-rank test to compare differences in survival. Patients were censored at the time of last follow-up. Statistical analyses were performed using GraphPad Prism 8.0 (GraphPad Inc., San Diego, CA, USA). A p value <0.05 (two-tailed) was considered statistically significant.

A total of 40 patients were included in this study. Their demographic and clinical characteristics are presented in Table 1 . The patients were mainly men (77.5%), with a median age of 63.8 years Mycophenolate mofetil (MMF) or mycophenolic acid (MPA) was being taken by 34 patients (85%), mTOR inhibitors were being administered to 6 (15%) patients, and steroids were taken by 23 (57.5%) patients. The median interval between the onset of symptoms and COVID-19 diagnosis was 4 days (IQR: 3−7 days). All but two patients had a fever. Respiratory (n=34, 85%) and gastrointestinal (n=31, 77.5%) symptoms were the most common clinical manifestations. Twenty-one patients had a non-severe clinical presentation, whereas 19 had a severe clinical course. During follow-up, the mortality rate was found to be 22.5% (9/40). The management of immunosuppression and the antiviral and immunomodulatory drugs administered to the study patients upon COVID-19 diagnosis are described in Table 2 .

A total of 118 upper respiratory specimens were analyzed (median of three swabs per patient [IQR: 2−3 swabs]). The median viral load was 5.17 log 10 copies/reaction (IQR: 3.80−6.69) at diagnosis (between day 0 and day 14 after symptom onset). A total of 29 patients (74.4%) had their peak viral load at admission, and two patients hospitalized at day 10 and day 11 after symptom onset had negative RT-PCR results at admission and during the follow-up. In these two cases, COVID-19 was initially diagnosed based on the presence of typical pulmonary lesions on

This article is protected by copyright. All rights reserved chest CT and subsequently confirmed by positive SARS-CoV-2 serology tests. The viral load at admission was not statistically different between severe and non-severe patients (6.22 log 10 copies/reaction versus 5.17 log 10 copies/reaction, respectively, p=0.29) and was not predictive of disease severity (area under the ROC curve = 0.595, p=0.31) at admission, at the peak of viral load ( Figure 1a and 1b) , or during the course of the disease ( Figure 2 ). Recipient age (ρ=0.23, p=0.16, Figure 3 ) and sex (p=0.05) were marginally associated with the viral load. Notably, patients receiving steroid therapy and not presenting gastrointestinal symptoms displayed a higher viral load (Table 3 ). There was no correlation between the time from symptom onset and viral loads in nasopharyngeal swabs at admission (ρ=0.261, p=0.11). Similar results were observed for SARS-CoV-2 RNAaemia (ρ=0.336, p=0.15). Moreover, no correlation was evident between maximum viral load and inflammatory markers, including interleukin (IL)-6 (ρ=0.041, p=0.81) and Creactive protein (CRP, ρ=0.001, p=0.99). Among patients with an initial positive RT-PCR test result (n=37), no patient showed a viral clearance before D21. Fifteen (38.5%) patients displayed a positive viral load greater than 3 log 10 copies/reaction after D10, and ten patients (24.4 %) showed persistent viral shedding after D30 (Figure 2 ). Furthermore, two non-survivors harbored high viral loads (4.55 log 10 copies/reaction and 4.26 log 10 copies /reaction), whereas other patients were characterized by low RNAaemia (< 2.16 log 10 copies/reaction). With regard to immunosuppressive therapy, patients receiving CNI tended to have more positive RNAaemia albeit not significantly so (8/26 versus 0/5, respectively, p=0.29).

There were no correlations between SARS-CoV-2 RNAaemia and viral loads in nasopharyngeal swabs both at admission (ρ=0.375, p=0.13) and during follow-up (ρ=0.159, p=0.41).

This article is protected by copyright. All rights reserved

A total of 116 samples from 35 patients were analyzed, with a median of three sera tested per patient (IQR: 2−4 sera). All survivors were seropositive at follow-up. Four non-survivors had negative serology at their time of death, which occurred on D7, D10, D15, and D16. The two patients with a negative SARS-CoV-2 RT-PCR result had positive serology, with one patient showing positive serology at the time of diagnosis. Among the 25 samples tested before D8, six (24%) were seropositive, whereas all samples tested after D14 were seropositive ( Figure 5 ). The kinetics of the antibodies showed that a stable titer of IgG antibodies was maintained until D59, suggesting persistence of immunity for at least until two months after infection ( Figure 6 ).

Notably, IgM and IgG antibody levels and delays in seroconversion were not correlated with COVID-19 severity (Figure 7a and 7b ).

In this retrospective study conducted in a sample of 40 immunocompromised KTR hospitalized for COVID-19, we precisely determined the temporal evolution of nasopharyngeal and plasma SARS-CoV-2 loads, as well as the serological response to the virus. All parameters were correlated with patient characteristics, disease severity, and clinical outcomes. In our study, the viral load in the respiratory specimens of most patients was at the peak at the time of diagnosis. This finding is in line with those previously reported for the general population. [9] [10] [11] Based on the data we analyzed, the viral load at the time of diagnosis did not predict the severity of the disease.

Moreover, viral loads were not related to inflammatory markers that have been previously associated with COVID-19 severity. 12 Reports on the relationship between viral load and disease severity are contradictory; three studies showed no correlation between the severity of the disease and the viral load in respiratory specimens, 10,11,13 whereas Liu et al. 14 described a higher viral load in patients with more severe disease.

In our immunocompromised population with a median follow-up of 53 days, the duration of viral detection in the respiratory tract was longer compared to that in the general population. More than a third of our patients displayed a high viral load after D10. Furthermore, almost a quarter of them still had viral shedding at D30; in contrast, in immunocompetent populations, the median duration of viral shedding was 20 days. 15 Isolation was stopped after two consecutively negative RT-PCR tests in nasopharyngeal swabs. Notably, this approach generally resulted in prolonged isolation periods. Only eight of the 40 study patients had evidence of two consecutively negative RT-PCR

This article is protected by copyright. All rights reserved tests in nasopharyngeal swabs during follow-up (median duration: 53 days). These figures seem longer that those reported for the general population. Notably, the Centers for Disease Control and Prevention (CDC) recommend 10-day isolation for the immunocompetent population. 16 SARS-CoV-2 RNAaemia was positive in 32% of our KTR with COVID-19. To our knowledge, SARS-CoV-2 RNAaemia in immunocompromised patients had not been previously described.

Nonetheless, this finding is in accordance with what was observed in the general population (ranging from 10.4% to 41% positivity for RNAaemia). 12, 15, 17 Our study shows that RNAaemia is associated with disease severity and mortality in KTR patients. However, published data on the subject are mixed. In studies conducted by Huang et al. 15 and Zheng et al. 17 , RNAaemia was not associated with COVID-19 severity, whereas in the cohort study carried out by Chen et al. 12 positive RNAaemia was correlated with highly elevated IL-6 plasma leveland was only detected in critically ill patients. In the study by Hadjadj et al. 13 , patients with severe and critical COVID-19 had higher plasma viral loads than those with mild and moderate disease. The pathophysiological mechanism of the association between COVID-19 severity and plasma viral load is still unclear;

perhaps the cytokine storm that affects COVID-19 severity could enhance RNAaemia by causing increased vascular permeability, or a significant viral load could trigger the cytokine storm. 12 Regarding the SARS-CoV-2 humoral response, this is the largest study with the longest follow-up in an immunocompromised population. All but four patients had positive serology during the follow-up. The four negative patients were tested early in the course of the disease and died shortly after. A total of 13 (43.3%) patients displayed positive serology before D15, supporting the potential usefulness of serology tests for acute diagnosis. All patients harbored SARS-CoV-2 antibodies from D15 onwards. Data on the serological response to SARS-CoV-2 in immunocompromised populations remain scanty. In a study from the United States, nine patients infected with SARS-CoV-2 after a solid organ transplant had positive IgG serology, with a delay of seroconversion between D6 and D27. 18 Zhao et al. 19 reported a delayed antibody response in a patient co-infected with COVID-19, HIV, and hepatitis C. In the general population, studies have reported seroconversion for all patients between the third and fourth week after symptom onset, which is concordant with our findings. These results suggest that the anti-SARS-CoV-2 humoral response is not significantly impaired in our immunocompromised population. 20, 21, 22 Notably, the

This article is protected by copyright. All rights reserved delay after transplantation was long in our cohort, and only one patient had undergone depleting induction therapy during the year preceding COVID-19. The level of IgG remained steady until two months after onset of symptoms. Although the neutralizing effect of the antibodies was not studied here, it is encouraging that IgG levels are correlated with a neutralizing effect in the general population. 10, 20 To our knowledge, this is the first report that provides a precise assessment of SARS-CoV-2 virological and antibody response kinetics in an immunocompromised population, with a followup for two months after symptom onset. However, several caveats need to be considered. First, the small sample size poses a limitation regarding the ability to generalize our conclusions. Second, the lack of data from some patients represents a potential bias. Finally, retrospective cohort studies are prone to unavoidable confounding or residual confounding on unmeasured variables.

In summary, our data indicate that 1) SARS-CoV-2 shedding from the upper respiratory tract is prolonged in KTR patients, indicating the requirement for prolonged protective measures for these patients; 2) the SARS-CoV-2 plasma load is associated with COVID-19 severity and mortality,

whereas the viral load of the upper respiratory tract is not; and 3) based on the presence of antibodies in all samples collected by us after the second week of symptom onset, the SARS-CoV-2 humoral response in our immunocompromised population does not show serious impairment and the antibodies persist until two months after COVID-19 symptom onset.

This article is protected by copyright. All rights reserved

This study was supported by the Strasbourg University Hospital (COVID-HUS study-HUS N°7760).

The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. Dr. Caillard reports personal fees and non-financial support from Novartis, non-financial support from Sanofi, and non-financial support from Astellas, unrelated to the current study. The other authors have no conflicts of interest to disclose.

Data supporting the findings from this study are available from the corresponding author upon reasonable request. 

Ilies

This article is protected by copyright. All rights reserved 

Xiang F, Wang X, He X, et al. 

This article is protected by copyright. All rights reserved 

A Novel Coronavirus from Patients with Pneumonia in China

RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

Coronavirus-disease-2019-covid-19-critical-care-and-airwaymanagement-issues

Procedure for the pulmonary management of non-ICU patients hospitalized in the context of the COVID-19 pandemic

A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial

World Health Organization. Molecular assays to diagnose COVID-19: Summary table of available protocols

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Temporal dynamics in viral shedding and transmissibility of COVID-19

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients. medRxiv

Viral dynamics in mild and severe cases of COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet

Discontinuation of Isolation for Persons with COVID -19 Not in Healthcare Settings

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

Clinical Outcomes and Serologic Response in Solid Organ Transplant Recipients with COVID-19: A Case Series from the United States

Early Virus Clearance and Delayed Antibody Response in a Case of Coronavirus Disease 2019 (COVID-19) With a History of Coinfection With Human Immunodeficiency Virus Type 1 and Hepatitis C Virus

Accepted Article

This article is protected by copyright. All rights reserved